已发表的部分文献: 标题:Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.作者:Todorova K, Metodiev MV, Metodieva G, Mincheff M, Fernández N, Hayrabedyan S;杂志名称:Horm Cancer 标题:TGF-β1 increases viral burden and promotes HIV-1 latency in primary differentiated human bronchial epithelial cells.作者:Chinnapaiyan S, Dutta RK, Nair M, Chand HS, Rahman I, Unwalla HJ;杂志名称:Sci Rep 标题:LncRNA SNHG16 induced by TFAP2A modulates glycolysis and proliferation of endometrial carcinoma through miR-490-3p/HK2 axis.作者:Zhang G, Ma A, Jin Y, Pan G, Wang C;杂志名称:Am J Transl Res 标题:METTL3-mediated pre-miR-665/DLX3 m6A methylation facilitates the committed differentiation of stem cells from apical papilla.作者:Gu T, Guo R, Fang Y, Xiao Y, Chen L, Li N, Ge XK, Shi Y, Wu J, Yan M, Yu J, Li Z;杂志名称:Exp Mol Med 标题:dCas9-HDAC8-EGFP fusion enables epigenetic editing of breast cancer cells by H3K9 deacetylation.作者:Rahman MM, Tollefsbol TO;杂志名称:Eur J Cell Biol Epigentek 公司是全球领先的表观遗传学相关研究的技术创新者和产品开发供应商。开发了超过700多个专利产品,为表观遗传学方面的研究和新药研发提供全面系统的解决方案,涵盖样品制备、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、组蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等领域,提供小分子抑制剂、蛋白质、抗体、以及分析试剂盒产品。